Allergic RhinitisNCT07453771
Safety and Efficacy of Small Extracellular Vesicles Nebulizer in Patients With Allergic Rhinitis Complicated With Asthma
A study testing hUC-MSC-sEV-002 Nebulizer and hUC-MSC-sEV-002 Mimetic (Normal Saline) in people with Allergic Rhinitis and Asthma, run by The Affiliated Hospital of Qingdao University at 5 sites in China.
Trial summary
This trial aims to evaluate the safety, tolerability and efficacy of hUC-MSC-sEV-002 nebulizer in patients with allergic rhinitis and asthma. It consists of two parts: ① Single-center dose exploration (The Affiliated Hospital of Qingdao University): A 3+3 escalation design will test three doses (1×10⁸, 1×10⁹, 1×10¹⁰… Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Allergic Rhinitis, Asthma
- What is being tested?
- hUC-MSC-sEV-002 Nebulizer and hUC-MSC-sEV-002 Mimetic (Normal Saline)
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 18 participants
- Where
- 5 sitesChina
- Study dates
- 5 Mar 2026to 31 Aug 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Aged 18-60 years, regardless of gender;
- Patients with moderate to severe allergic rhinitis (with sleep/work/study/daily activity impairment or distressing symptoms) meeting the diagnostic criteria of the international Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines, positive for at least one inhalant allergen skin prick test, and concurrent asthma complying with the Global Initiative for Asthma (GINA) 2022 guidelines;
- Suboptimal response to antiallergic medication treatment for one year prior to enrollment;
- Patients who decline allergen-specific immunotherapy, or have no available specific therapy for the relevant allergen, or failed allergen-specific immunotherapy;
- Females of childbearing potential must agree to avoid pregnancy during study participation and for 30 days after the final visit;
- Subjects or their legal representatives must be able to sign the informed consent form and comply with the study requirements for medication administration and follow-up.
Who cannot join
- Complicated with other nasal and sinus diseases that may affect the reasonable assessment of efficacy and/or safety;
- Suffering from uncontrolled asthma or poorly controlled asthma symptoms;
- Suffering from malignant tumors, severe immune diseases, long-term use of immunosuppressants, or immunodeficiency;
- Having unstable conditions due to respiratory tract infection and/or acute asthma exacerbation within 4 weeks prior to the initial screening visit;
- Currently receiving treatment with beta-blockers or angiotensin-converting enzyme (ACE) inhibitors;
- Suffering from mental illnesses;
Show all 13Show fewer
- Suffering from severe systemic diseases, such as cases of peptic ulcers, diabetes mellitus, and heart failure;
- Specific infections such as syphilis, leprosy, and tuberculosis;
- Females who are currently pregnant, planning to become pregnant soon, or breastfeeding;
- Patients who are currently participating in other clinical trials or have participated in other clinical trials within 30 days prior to the initial screening visit;
- Patients who are currently receiving allergen desensitization therapy or biologic therapy;
- Positive for hepatitis B surface antigen, hepatitis C virus antibody, syphilis serological antibody, or human immunodeficiency virus (HIV) antibody;
- In addition to the above conditions, patients will be excluded if the investigators consider them unsuitable for participation in this clinical study for other reasons.
Trial locations and contacts
5 sites in 1 country. Contact the study team or a site near you to ask about taking part.
5 sites in 1 country
China5 sites
Chongqing General Hospital
Chongqing, 401121
Wei Yuan, MD, +8613368228269, yuanwei@ucas.ac.cn
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510080
Qingling Fu, MD, +8613699726862, fuqingl@mail.sysu.edu.cn
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510630
Qintai Yang, MD, +8613724859848, yangqint@mail.sysu.edu.cn
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, 266100
Shengnan Zhang, MMed, +8618661808533, zhangshengnan0102@163.com
The Second Affiliated Hospital of Shandong First Medical University
Tai’an, Shandong, 271000
Deli Wang, MMed, +8615621335297, WDLWNY@163.com
About this study
Official title: Safety and Preliminary Efficacy of Small Extracellular Vesicles (Code: hUC-MSC-sEV-002) Nebulizer in Patients With Allergic Rhinitis Complicated With Asthma: A Multicenter, Prospective, Randomized, Double-Blind Phase I/II Clinical Study
This trial aims to evaluate the safety, tolerability and efficacy of hUC-MSC-sEV-002 nebulizer in patients with allergic rhinitis and asthma. It consists of two parts: ① Single-center dose exploration (The Affiliated Hospital of Qingdao University): A 3+3 escalation design will test three doses (1×10⁸, 1×10⁹, 1×10¹⁰ particles/mL) to determine the maximum tolerated dose (MTD).Three subjects will be enrolled in each dose group. If no Dose-Limiting Toxicity (DLT) is observed among the 3 subjects, the study may proceed to the next dose exploration. If 1 out of the 3 subjects experiences DLT, an additional 3 subjects will be enrolled in the same dose group; the study may move to the next dose exploration only if no DLT is observed in these additional 3 subjects. If more than 1 out of the 3 subjects develops DLT, the previous dose group will be defined as the MTD. A total of at least 9 and at most 18 subjects will be recruited for this clinical trial. ② Multi-center case expansion: Participants will be randomized 2:1 to hUC-MSC-sEV-002 or placebo groups for efficacy comparison.Eligibility criteria: 18-60 years old; moderate-to-severe allergic rhinitis (ARIA guidelines) with positive inhaled allergen skin test; asthma diagnosed per GINA 2022; signed informed consent.Intervention: Nebulization once daily (5 times/week, 2 weeks, 10 doses total). Follow-up visits at baseline, Week 2, 4, 12, 24, including symptom scales, lung function tests, nasal endoscopy, nasal exhaled nitric oxide test, chest X-ray, blood tests, and electrocardiogram. The trial is approved by the Medical Ethics Committee of The Affiliated Hospital of Qingdao University (No. QYFYEC2025-192). Participants may withdraw anytime without affecting medical care. Study period: Aug 2025-Aug 2027. Sample size: 9-18 for Part 1; Part 2 size based on Part 1 results.
Read the detailed description
Allergic rhinitis is an independent risk factor for asthma. As inflammatory disorders affecting the upper and lower airways respectively, allergic rhinitis and asthma share similar pathogenesis and interact with each other, thus being recognized as "one airway, one disease". Their incidence rates are increasing year by year with a wide distribution, and they often coexist. These conditions have become an important issue affecting people's quality of life worldwide and imposed a heavy economic burden on society. In the treatment of allergic rhinitis complicated with asthma, glucocorticoids, antihistamines, leukotriene receptor antagonists and other agents are the most commonly used drugs. However, long-term use of these drugs is prone to induce various adverse reactions. Moreover, drug resistance and intolerance observed in some patients have also limited the widespread application of these medications. Therefore, there is an urgent need for novel therapeutic approaches for allergic diseases.
Small extracellular vesicles derived from mesenchymal stem cells not only possess immunomodulatory functions similar to those of mesenchymal stem cells, but also exhibit more advantages in clinical applications, including no tumorigenic risk, small size, stable performance, easy transportation and preservation, low immunogenicity, and the ability to penetrate biological barriers. Therefore, they hold great potential and broad application prospects in the treatment of allergic rhinitis complicated with asthma.
This is a multicenter, prospective, randomized, double-blind, placebo-controlled, dose-finding clinical trial, designed to evaluate the safety and preliminary efficacy of nebulized human umbilical cord blood mesenchymal stem cell-derived small extracellular vesicles (code: hUC-MSC-sEV-002) in the treatment of allergic rhinitis complicated with asthma. The trial consists of two phases, namely the dose-finding phase (Phase I clinical trial) and the cohort expansion phase (Phase II clinical trial). It encompasses three study periods: the screening period (Visit 0, Weeks -2 to 0), the treatment period (Visit 1, Week 2), and the follow-up period (Visit 2, Week 4; Visit 3, Week 12; Visit 4, Week 24). The scheduled visit plan includes baseline assessment, the end of Week 2, the end of Week 4, Week 12, and Week 24.
Primary safety endpoints include dose-limiting toxicities (DLT) associated with nebulized hUC-MSC-sEV-002, covering the following aspects: the incidence of drug-related adverse reactions occurring within the short-term post-treatment period (0 to 24 hours); the incidence of drug-related adverse reactions within 2 weeks of treatment; changes in vital signs, complete blood count plus C-reactive protein (CRP), urine routine, liver and kidney function, immune profile panel (IgG, IgA, IgM, C3, C4), and electrocardiogram (ECG) from baseline to the end of Week 2 of treatment.
Secondary safety endpoints include the incidence of adverse events at Week 12 and Week 24 of treatment; changes in vital signs, complete blood count, urine routine, liver and kidney function, immune profile panel, and electrocardiogram (ECG) from baseline to Week 12 and Week 24 of treatment; pulmonary function tests at Week 2 and Week 24 of treatment; and chest X-ray examination at Week 24 of treatment.
Questionnaire (RQLQ) scores, Total Nasal Symptom Score (TNSS), Visual Analog Scale (VAS) scores, Asthma Control Test (ACT) scores, forced expiratory volume in one second (FEV₁), and peak expiratory flow (PEF) at Week 24 of treatment.
Secondary efficacy endpoints include the percentage changes from baseline in the Rhinitis Quality of Life Questionnaire (RQLQ) scores, Total Nasal Symptom Score (TNSS), and Visual Analog Scale (VAS) scores at the end of Week 2, end of Week 4, and Week 12 of treatment; the percentage changes from baseline in forced expiratory volume in one second (FEV₁), peak expiratory flow (PEF), and Asthma Control Test (ACT) scores at the end of Week 2, end of Week 4, and Week 12 of treatment; the percentage changes from baseline in total serum IgE, specific IgE, and IgG4 levels at Week 12 and Week 24 of treatment; and the changes in nasal endoscopy findings and nasal exhaled nitric oxide test results from baseline to Week 12 and Week 24 of treatment.
Exploratory endpoints include the changes from baseline in plasma cytokines (IFN-γ, IL-6, IL-4, IL-5, IL-13), peripheral blood lymphocytes, and the subsets of Th1, Th2, Th17 and ILC2 at the end of Week 2, Week 12 and Week 24 of treatment; as well as the changes from baseline in nasal secretion cytokines (ECP, IL-6, IFN-γ, IL-5, IL-13, IL-33) at the end of Week 2, Week 12 and Week 24 of treatment.
All adverse events occurring in all subjects during the clinical study shall be monitored closely. The adverse event forms shall be completed in a timely manner, with detailed documentation of clinical manifestations, severity, time of onset, duration, measures taken and clinical outcomes. The study shall not be initiated until the clinical study protocol and the informed consent form have been submitted to and approved by the Institutional Review Board (IRB).
- Conditions
- Allergic Rhinitis, Asthma
- Being tested
- hUC-MSC-sEV-002 Nebulizer, hUC-MSC-sEV-002 Mimetic (Normal Saline)
- Keywords
- Small extracellular vesicles, Nebulizer formulation, Allergic rhinitis, Asthma, Randomized, double-blind
- Medical subject headings
- Rhinitis, Allergic, Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
hUC-MSC-sEV-002 NebulizerOther
Nebulization therapy, once daily, 5 nebulizations per week, for 2 consecutive weeks, totaling 10 times.
hUC-MSC-sEV-002 Mimetic (Normal Saline)Other
Nebulization therapy, once daily, 5 nebulizations per week, for 2 consecutive weeks, totaling 10 times.
| Study group | Role | What they receive |
|---|---|---|
| hUC-MSC-sEV-002 nebulizer | Experimental | hUC-MSC-sEV-002 nebulizer, nebulization therapy, once daily, 5 nebulizations per week, for 2 consecutive weeks, totaling 10 times. Receives: Other: hUC-MSC-sEV-002 Nebulizer |
| hUC-MSC-sEV-002 Mimetic (Normal Saline) | Placebo comparator | A control arm is established in Phase II of the clinical trial.hUC-MSC-sEV-002 Mimetic (Normal Saline), nebulization therapy, once daily, 5 nebulizations per week, for 2 consecutive weeks, totaling 10 times. Receives: Other: hUC-MSC-sEV-002 Mimetic (Normal Saline) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
It consists of 7 domains and 28 items, with each item scored on a scale of 0 to 6. Each domain is scored independently, and the sum of all domain scores yields the total RQLQ score, which ranges from 0 to 168. A higher total score indicates a greater negative impact of the disease on the patient's quality of life.
Measured: At Week 24
Forced Expiratory Volume in One Second (FEV1)
Pulmonary function tests are conducted to obtain the value of FEV1, with the unit of FEV1 being liters (L). A percentage of the measured FEV1 value relative to the predicted value of 80% or higher is defined as normal.
Measured: At Week 24
Drug-related adverse reaction rate
The incidence of treatment-related adverse events within the short-term post-treatment period (0 to 24 hours);The incidence of treatment-related adverse events at 2 weeks post-treatment.
Measured: In the short term after treatment (0-24 hours)；At Week 2
Blood Pressure
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) shall be measured separately. The reference range for SBP is 90 mmHg to 139 mmHg, and the reference range for DBP is 60 mmHg to 89 mmHg.
Measured: At Week 2
Changes in routine blood test
We performed routine blood tests via venous blood collection and recorded any changes compared with baseline.
Measured: At Week 2
Changes in routine urine test
Urine specimens were collected for routine urinalysis, and any abnormal changes from baseline were documented.
Measured: At Week 2
Whether abnormal changes occurred in the ECG
Electrocardiography (ECG) will be performed to evaluate whether there are any abnormalities in the patient's heart rate or cardiac rhythm.
Measured: At Week 2
Total Nasal Symptom Score (TNSS)
It consists of 4 items, with each item scored on a scale of 0 to 3. The total score ranges from 0 to 12, with a higher total score indicating more severe disease symptoms.
Measured: At Week 24
Visual Analog Scale (VAS)
It is used to assess the severity of symptoms, with the total score ranging from 0 to 10. A higher total score indicates more severe disease symptoms.
Measured: At Week 24
Asthma Control Test (ACT)
It is used to assess asthma control, with the total score ranging from 0 to 25. A higher total score indicates better asthma control.
Measured: At Week 24
Peak Expiratory Flow (PEF)
Pulmonary function tests are conducted to obtain the value of PEF, with the unit of PEF being liters per second (L/s). A percentage of the measured PEF value relative to the predicted value of 80% or higher is defined as normal.
Measured: At Week 24
Heart Rate
The unit of heart rate is beats per minute, with a normal range of 60 to 100 bpm.
Measured: At Week 2
Body Temperature
The unit is degrees Celsius (°C), with a normal range of 36.0 °C to 37.0 °C.
Measured: At Week 2
C-reactive protein (CRP)
Venous blood sampling is performed for C-reactive protein (CRP) testing.The unit is mg/L, with a normal reference range of 0 to 5 mg/L.
Measured: At Week 2
Alanine aminotransferase (ALT)
Venous blood sampling is performed for liver function tests. Alanine aminotransferase (ALT) is measured in U/L, with a normal reference range of 7-40 U/L for females and 9-50 U/L for males.
Measured: At Week 2
Creatinine
Venous blood sampling is performed for renal function tests.The unit for creatinine is μmol/L, with a normal reference range of 41-81 μmol/L for females and 57-111 μmol/L for males.
Measured: At Week 2
IgG, IgA, IgM, C3 ,C4
Venous blood sampling is performed for five immunological indicators, which mainly includes IgG, IgA, IgM, C3 and C4.The units for all the above indicators are g/L. Normal reference ranges:IgG: 8.6-17.4 g/L；IgA: 1.0-4.2 g/L；IgM: 0.3-2.2 g/L；C3: 0.7-1.4 g/L；C4: 0.1-0.4 g/L.
Measured: At Week 2
Aspartate aminotransferase (AST)
Venous blood sampling is performed for liver function tests. Aspartate aminotransferase (AST) is measured in U/L, with a normal reference range of 13-35 U/L for females and 15-40 U/L for males.
Measured: At Week 2
Secondary outcomes (24)
Adverse event rate
The incidence of adverse events at 12 and 24 weeks post-treatment.
Measured: At Week 12; At Week 24
Blood Pressure
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) shall be measured separately. The reference range for SBP is 90 mmHg to 139 mmHg, and the reference range for DBP is 60 mmHg to 89 mmHg.
Measured: At Week 12; At Week 24
Changes in routine blood test
We performed routine blood tests via venous blood collection and recorded any changes compared with baseline.
Measured: At Week 12; At Week 24
Changes in routine urine test
Urine specimens were collected for routine urinalysis, and any abnormal changes from baseline were documented.
Measured: At Week 12; At Week 24
Whether abnormal changes occurred in the ECG
Electrocardiography (ECG) will be performed to evaluate whether there are any abnormalities in the patient's heart rate or cardiac rhythm.
Measured: At Week 12; At Week 24
Chest X-ray
A chest X-ray shall be performed at Week 24 of treatment to evaluate for any abnormal pulmonary imaging findings.
Measured: At Week 24
Rhinitis-Conjunctivitis Quality of Life Questionnaire（RQLQ）
It consists of 7 domains and 28 items, with each item scored on a scale of 0 to 6. Each domain is scored independently, and the sum of all domain scores yields the total RQLQ score, which ranges from 0 to 168. A higher total score indicates a greater negative impact of the disease on the patient's quality of life.
Measured: At Week 2; At Week 4; At Week 12
Forced Expiratory Volume in 1 second（FEV1）
Pulmonary function tests are conducted to obtain the value of FEV1, with the unit of FEV1 being liters (L). A percentage of the measured FEV1 value relative to the predicted value of 80% or higher is defined as normal.
Measured: At Week 2; At Week 4; At Week 12; At Week 24
Total Serum Immunoglobulin E (IgE)
Venous blood samples are collected for total serum IgE testing, with the unit of IU/mL. The normal range is 0 to 100 IU/mL.
Measured: At Week 12; At Week 24
Nasal endoscopy
Nasal endoscopy shall be performed to assess for any structural abnormalities or abnormal hyperplastic lesions in the nasal cavity, and to evaluate for any abnormal changes in the nasal mucosa.
Measured: After 12 weeks of treatment；After 24 weeks of treatment
Nasal Exhaled Nitric Oxide
The concentration of nitric oxide in nasal exhalation is measured using a nasal exhaled nitric oxide analyzer.
Measured: At Week 12; At Week 24
Heart Rate
The unit of heart rate is beats per minute, with a normal range of 60 to 100 bpm.
Measured: At Week 12; At Week 24
Body Temperature
The unit is degrees Celsius (°C), with a normal range of 36.0 °C to 37.0 °C.
Measured: At Week 12; At Week 24
C-reactive protein (CRP)
Venous blood sampling is performed for C-reactive protein (CRP) testing.The unit is mg/L, with a normal reference range of 0 to 5 mg/L.
Measured: At Week 12; At Week 24
Alanine aminotransferase (ALT)
Venous blood sampling is performed for liver function tests. Alanine aminotransferase (ALT) is measured in U/L, with a normal reference range of 7-40 U/L for females and 9-50 U/L for males.
Measured: At Week 12; At Week 24
Creatinine
Venous blood sampling is performed for renal function tests.The unit for creatinine is μmol/L, with a normal reference range of 41-81 μmol/L for females and 57-111 μmol/L for males.
Measured: At Week 12; At Week 24
IgG, IgA, IgM, C3,C4
Venous blood sampling is performed for five immunological indicators, which mainly includes IgG, IgA, IgM, C3 and C4.The units for all the above indicators are g/L. Normal reference ranges:IgG: 8.6-17.4 g/L；IgA: 1.0-4.2 g/L；IgM: 0.3-2.2 g/L；C3: 0.7-1.4 g/L；C4: 0.1-0.4 g/L.
Measured: At Week 12; At Week 24
Peak Expiratory Flow (PEF)
Pulmonary function tests are conducted to obtain the value of PEF, with the unit of PEF being liters per second (L/s). A percentage of the measured PEF value relative to the predicted value of 80% or higher is defined as normal.
Measured: At Week 2; At Week 4;At Week 12; At Week 24
Total Nasal Symptom Score (TNSS)
It consists of 4 items, with each item scored on a scale of 0 to 3. The total score ranges from 0 to 12, with a higher total score indicating more severe disease symptoms.
Measured: At Week 2; At Week 4; At Week 12
Visual Analog Scale (VAS)
It is used to assess the severity of symptoms, with the total score ranging from 0 to 10. A higher total score indicates more severe disease symptoms.
Measured: At Week 2; At Week 4; At Week 12
Asthma Control Test (ACT)
It is used to assess asthma control, with the total score ranging from 0 to 25. A higher total score indicates better asthma control.
Measured: At Week 2; At Week 4; At Week 12
Specific Immunoglobulin E (sIgE)
Venous blood samples are collected for specific IgE (sIgE) testing, with the unit of kU/L. The normal value is less than 60 kU/L.
Measured: At Week 12; At Week 24
Immunoglobulin G4 (IgG4)
Venous blood samples are collected for IgG4 testing, with the unit of g/L. The normal range is 0.03 to 2.01 g/L.
Measured: At Week 12; At Week 24
Aspartate aminotransferase (AST)
Venous blood sampling is performed for liver function tests. Aspartate aminotransferase (AST) is measured in U/L, with a normal reference range of 13-35 U/L for females and 15-40 U/L for males.
Measured: At Week 12; At Week 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Mar 2026
- Study start5 Mar 2026 (estimated)
- Primary completion28 Feb 2027 (estimated)
- Study completion31 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Allergic RhinitisStudies of the same condition, open and under way.
- More trials run by The Affiliated Hospital of Qingdao UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a combined Phase 1/Phase 2 randomized, double-blind, placebo-controlled trial with distinct designs for each phase. Phase 1 is a dose-escalation stage to determine the safe dose range of hUC-MSC-sEV-002 nebulizer, without a control group; only subjects receive different doses of the investigational drug. Phase 2 is an expansion stage: eligible patients with allergic rhinitis and asthma are randomly assigned to the experimental (hUC-MSC-sEV-002 nebulizer) or control (matched placebo) group at 2:1 via block randomization. Both groups have identical administration route, frequency and treatment course. Double-blinding is maintained throughout the study for participants, investigators and outcome assessors until data locking and unblinding.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 18 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The Affiliated Hospital of Qingdao University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, jiangyan, The Affiliated Hospital of Qingdao University
- Investigators
- Yan Jiang, MD, Principal investigator, The Affiliated Hospital of Qingdao University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07453771
- Sponsor's protocol ID
- QYFYEC2025-192
- Status last verified
- Feb 2026
- First submitted
- 23 Dec 2025
- Last updated
- 6 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The informed consent form of this study does not include clauses authorizing IPD sharing. As a Phase I/II exploratory study, the data involves sensitive medical information and preliminary research results. To protect participants' privacy and comply with ethical and regulatory requirements, the data will not be shared.
Study at a glance
From the registry record, last updated by the sponsor on 6 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety and Preliminary Efficacy of Small Extracellular Vesicles (Code: hUC-MSC-sEV-002) Nebulizer in Patients With Allergic Rhinitis Complicated With Asthma: A Multicenter, Prospective, Randomized, Double-Blind Phase I/II Clinical Study
- ClinicalTrials.gov ID
- NCT07453771
- Acronym / sponsor ID
- QYFYEC2025-192
- Conditions
- Allergic Rhinitis, Asthma
- Keywords
- Small extracellular vesicles, Nebulizer formulation, Allergic rhinitis, Asthma, Randomized, double-blind
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 18 participants (estimated)
- Lead sponsor
- The Affiliated Hospital of Qingdao UniversityUniversity, hospital or other
- Study start
- 5 Mar 2026 (estimated)
- Primary completion
- 28 Feb 2027 (estimated)
- Study completion
- 31 Aug 2027 (estimated)
- First posted
- 6 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This trial aims to evaluate the safety, tolerability and efficacy of hUC-MSC-sEV-002 nebulizer in patients with allergic rhinitis and asthma. It consists of two parts: ① Single-center dose exploration (The Affiliated Hospital of Qingdao University): A 3+3 escalation design will test three doses (1×10⁸, 1×10⁹, 1×10¹⁰ particles/mL) to determine the maximum tolerated dose (MTD).Three subjects will be enrolled in each dose group. If no Dose-Limiting Toxicity (DLT) is observed among the 3 subjects, the study may proceed to the next dose exploration. If 1 out of the 3 subjects experiences DLT, an additional 3 subjects will be enrolled in the same dose group; the study may move to the next dose exploration only if no DLT is observed in these additional 3 subjects. If more than 1 out of the 3 subjects develops DLT, the previous dose group will be defined as the MTD. A total of at least 9 and at most 18 subjects will be recruited for this clinical trial. ② Multi-center case expansion: Participants will be randomized 2:1 to hUC-MSC-sEV-002 or placebo groups for efficacy comparison.Eligibility criteria: 18-60 years old; moderate-to-severe allergic rhinitis (ARIA guidelines) with positive inhaled allergen skin test; asthma diagnosed per GINA 2022; signed informed consent.Intervention: Nebulization once daily (5 times/week, 2 weeks, 10 doses total). Follow-up visits at baseline, Week 2, 4, 12, 24, including symptom scales, lung function tests, nasal endoscopy, nasal exhaled nitric oxide test, chest X-ray, blood tests, and electrocardiogram. The trial is approved by the Medical Ethics Committee of The Affiliated Hospital of Qingdao University (No. QYFYEC2025-192). Participants may withdraw anytime without affecting medical care. Study period: Aug 2025-Aug 2027. Sample size: 9-18 for Part 1; Part 2 size based on Part 1 results.
Detailed description
Allergic rhinitis is an independent risk factor for asthma. As inflammatory disorders affecting the upper and lower airways respectively, allergic rhinitis and asthma share similar pathogenesis and interact with each other, thus being recognized as "one airway, one disease". Their incidence rates are increasing year by year with a wide distribution, and they often coexist. These conditions have become an important issue affecting people's quality of life worldwide and imposed a heavy economic burden on society. In the treatment of allergic rhinitis complicated with asthma, glucocorticoids, antihistamines, leukotriene receptor antagonists and other agents are the most commonly used drugs. However, long-term use of these drugs is prone to induce various adverse reactions. Moreover, drug resistance and intolerance observed in some patients have also limited the widespread application of these medications. Therefore, there is an urgent need for novel therapeutic approaches for allergic diseases.
Small extracellular vesicles derived from mesenchymal stem cells not only possess immunomodulatory functions similar to those of mesenchymal stem cells, but also exhibit more advantages in clinical applications, including no tumorigenic risk, small size, stable performance, easy transportation and preservation, low immunogenicity, and the ability to penetrate biological barriers. Therefore, they hold great potential and broad application prospects in the treatment of allergic rhinitis complicated with asthma.
This is a multicenter, prospective, randomized, double-blind, placebo-controlled, dose-finding clinical trial, designed to evaluate the safety and preliminary efficacy of nebulized human umbilical cord blood mesenchymal stem cell-derived small extracellular vesicles (code: hUC-MSC-sEV-002) in the treatment of allergic rhinitis complicated with asthma. The trial consists of two phases, namely the dose-finding phase (Phase I clinical trial) and the cohort expansion phase (Phase II clinical trial). It encompasses three study periods: the screening period (Visit 0, Weeks -2 to 0), the treatment period (Visit 1, Week 2), and the follow-up period (Visit 2, Week 4; Visit 3, Week 12; Visit 4, Week 24). The scheduled visit plan includes baseline assessment, the end of Week 2, the end of Week 4, Week 12, and Week 24.
Primary safety endpoints include dose-limiting toxicities (DLT) associated with nebulized hUC-MSC-sEV-002, covering the following aspects: the incidence of drug-related adverse reactions occurring within the short-term post-treatment period (0 to 24 hours); the incidence of drug-related adverse reactions within 2 weeks of treatment; changes in vital signs, complete blood count plus C-reactive protein (CRP), urine routine, liver and kidney function, immune profile panel (IgG, IgA, IgM, C3, C4), and electrocardiogram (ECG) from baseline to the end of Week 2 of treatment.
Secondary safety endpoints include the incidence of adverse events at Week 12 and Week 24 of treatment; changes in vital signs, complete blood count, urine routine, liver and kidney function, immune profile panel, and electrocardiogram (ECG) from baseline to Week 12 and Week 24 of treatment; pulmonary function tests at Week 2 and Week 24 of treatment; and chest X-ray examination at Week 24 of treatment.
Questionnaire (RQLQ) scores, Total Nasal Symptom Score (TNSS), Visual Analog Scale (VAS) scores, Asthma Control Test (ACT) scores, forced expiratory volume in one second (FEV₁), and peak expiratory flow (PEF) at Week 24 of treatment.
Secondary efficacy endpoints include the percentage changes from baseline in the Rhinitis Quality of Life Questionnaire (RQLQ) scores, Total Nasal Symptom Score (TNSS), and Visual Analog Scale (VAS) scores at the end of Week 2, end of Week 4, and Week 12 of treatment; the percentage changes from baseline in forced expiratory volume in one second (FEV₁), peak expiratory flow (PEF), and Asthma Control Test (ACT) scores at the end of Week 2, end of Week 4, and Week 12 of treatment; the percentage changes from baseline in total serum IgE, specific IgE, and IgG4 levels at Week 12 and Week 24 of treatment; and the changes in nasal endoscopy findings and nasal exhaled nitric oxide test results from baseline to Week 12 and Week 24 of treatment.
Exploratory endpoints include the changes from baseline in plasma cytokines (IFN-γ, IL-6, IL-4, IL-5, IL-13), peripheral blood lymphocytes, and the subsets of Th1, Th2, Th17 and ILC2 at the end of Week 2, Week 12 and Week 24 of treatment; as well as the changes from baseline in nasal secretion cytokines (ECP, IL-6, IFN-γ, IL-5, IL-13, IL-33) at the end of Week 2, Week 12 and Week 24 of treatment.
All adverse events occurring in all subjects during the clinical study shall be monitored closely. The adverse event forms shall be completed in a timely manner, with detailed documentation of clinical manifestations, severity, time of onset, duration, measures taken and clinical outcomes. The study shall not be initiated until the clinical study protocol and the informed consent form have been submitted to and approved by the Institutional Review Board (IRB).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- This is a combined Phase 1/Phase 2 randomized, double-blind, placebo-controlled trial with distinct designs for each phase. Phase 1 is a dose-escalation stage to determine the safe dose range of hUC-MSC-sEV-002 nebulizer, without a control group; only subjects receive different doses of the investigational drug. Phase 2 is an expansion stage: eligible patients with allergic rhinitis and asthma are randomly assigned to the experimental (hUC-MSC-sEV-002 nebulizer) or control (matched placebo) group at 2:1 via block randomization. Both groups have identical administration route, frequency and treatment course. Double-blinding is maintained throughout the study for participants, investigators and outcome assessors until data locking and unblinding.
| Arm | Type | Receives |
|---|---|---|
| hUC-MSC-sEV-002 nebulizer | Experimental | Other: hUC-MSC-sEV-002 NebulizerhUC-MSC-sEV-002 nebulizer, nebulization therapy, once daily, 5 nebulizations per week, for 2 consecutive weeks, totaling 10 times. |
| hUC-MSC-sEV-002 Mimetic (Normal Saline) | Placebo comparator | Other: hUC-MSC-sEV-002 Mimetic (Normal Saline)A control arm is established in Phase II of the clinical trial.hUC-MSC-sEV-002 Mimetic (Normal Saline), nebulization therapy, once daily, 5 nebulizations per week, for 2 consecutive weeks, totaling 10 times. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Aged 18-60 years, regardless of gender;
- Patients with moderate to severe allergic rhinitis (with sleep/work/study/daily activity impairment or distressing symptoms) meeting the diagnostic criteria of the international Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines, positive for at least one inhalant allergen skin prick test, and concurrent asthma complying with the Global Initiative for Asthma (GINA) 2022 guidelines;
- Suboptimal response to antiallergic medication treatment for one year prior to enrollment;
- Patients who decline allergen-specific immunotherapy, or have no available specific therapy for the relevant allergen, or failed allergen-specific immunotherapy;
- Females of childbearing potential must agree to avoid pregnancy during study participation and for 30 days after the final visit;
Key exclusion criteria (13 listed)
- Complicated with other nasal and sinus diseases that may affect the reasonable assessment of efficacy and/or safety;
- Suffering from uncontrolled asthma or poorly controlled asthma symptoms;
- Suffering from malignant tumors, severe immune diseases, long-term use of immunosuppressants, or immunodeficiency;
- Having unstable conditions due to respiratory tract infection and/or acute asthma exacerbation within 4 weeks prior to the initial screening visit;
- Currently receiving treatment with beta-blockers or angiotensin-converting enzyme (ACE) inhibitors;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| hUC-MSC-sEV-002 NebulizerNebulization therapy, once daily, 5 nebulizations per week, for 2 consecutive weeks, totaling 10 times. | Other | hUC-MSC-sEV-002 nebulizer |
| hUC-MSC-sEV-002 Mimetic (Normal Saline)Nebulization therapy, once daily, 5 nebulizations per week, for 2 consecutive weeks, totaling 10 times. | Other | hUC-MSC-sEV-002 Mimetic (Normal Saline) |
Primary outcome
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
Time frame: At Week 24
It consists of 7 domains and 28 items, with each item scored on a scale of 0 to 6. Each domain is scored independently, and the sum of all domain scores yields the total RQLQ score, which ranges from 0 to 168. A higher total score indicates a greater negative impact of the disease on the patient's quality of life.
Forced Expiratory Volume in One Second (FEV1)
Time frame: At Week 24
Pulmonary function tests are conducted to obtain the value of FEV1, with the unit of FEV1 being liters (L). A percentage of the measured FEV1 value relative to the predicted value of 80% or higher is defined as normal.
Drug-related adverse reaction rate
Time frame: In the short term after treatment (0-24 hours)；At Week 2
The incidence of treatment-related adverse events within the short-term post-treatment period (0 to 24 hours);The incidence of treatment-related adverse events at 2 weeks post-treatment.
Blood Pressure
Time frame: At Week 2
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) shall be measured separately. The reference range for SBP is 90 mmHg to 139 mmHg, and the reference range for DBP is 60 mmHg to 89 mmHg.
Changes in routine blood test
Time frame: At Week 2
We performed routine blood tests via venous blood collection and recorded any changes compared with baseline.
Changes in routine urine test
Time frame: At Week 2
Urine specimens were collected for routine urinalysis, and any abnormal changes from baseline were documented.
Whether abnormal changes occurred in the ECG
Time frame: At Week 2
Electrocardiography (ECG) will be performed to evaluate whether there are any abnormalities in the patient's heart rate or cardiac rhythm.
Total Nasal Symptom Score (TNSS)
Time frame: At Week 24
It consists of 4 items, with each item scored on a scale of 0 to 3. The total score ranges from 0 to 12, with a higher total score indicating more severe disease symptoms.
Visual Analog Scale (VAS)
Time frame: At Week 24
It is used to assess the severity of symptoms, with the total score ranging from 0 to 10. A higher total score indicates more severe disease symptoms.
Asthma Control Test (ACT)
Time frame: At Week 24
It is used to assess asthma control, with the total score ranging from 0 to 25. A higher total score indicates better asthma control.
Peak Expiratory Flow (PEF)
Time frame: At Week 24
Pulmonary function tests are conducted to obtain the value of PEF, with the unit of PEF being liters per second (L/s). A percentage of the measured PEF value relative to the predicted value of 80% or higher is defined as normal.
Heart Rate
Time frame: At Week 2
The unit of heart rate is beats per minute, with a normal range of 60 to 100 bpm.
Body Temperature
Time frame: At Week 2
The unit is degrees Celsius (°C), with a normal range of 36.0 °C to 37.0 °C.
C-reactive protein (CRP)
Time frame: At Week 2
Venous blood sampling is performed for C-reactive protein (CRP) testing.The unit is mg/L, with a normal reference range of 0 to 5 mg/L.
Alanine aminotransferase (ALT)
Time frame: At Week 2
Venous blood sampling is performed for liver function tests. Alanine aminotransferase (ALT) is measured in U/L, with a normal reference range of 7-40 U/L for females and 9-50 U/L for males.
Creatinine
Time frame: At Week 2
Venous blood sampling is performed for renal function tests.The unit for creatinine is μmol/L, with a normal reference range of 41-81 μmol/L for females and 57-111 μmol/L for males.
IgG, IgA, IgM, C3 ,C4
Time frame: At Week 2
Venous blood sampling is performed for five immunological indicators, which mainly includes IgG, IgA, IgM, C3 and C4.The units for all the above indicators are g/L. Normal reference ranges:IgG: 8.6-17.4 g/L；IgA: 1.0-4.2 g/L；IgM: 0.3-2.2 g/L；C3: 0.7-1.4 g/L；C4: 0.1-0.4 g/L.
Aspartate aminotransferase (AST)
Time frame: At Week 2
Venous blood sampling is performed for liver function tests. Aspartate aminotransferase (AST) is measured in U/L, with a normal reference range of 13-35 U/L for females and 15-40 U/L for males.
24 secondary outcomes
Adverse event rate
Time frame: At Week 12; At Week 24
Blood Pressure
Time frame: At Week 12; At Week 24
Changes in routine blood test
Time frame: At Week 12; At Week 24
Changes in routine urine test
Time frame: At Week 12; At Week 24
Whether abnormal changes occurred in the ECG
Time frame: At Week 12; At Week 24
Chest X-ray
Time frame: At Week 24
Rhinitis-Conjunctivitis Quality of Life Questionnaire（RQLQ）
Time frame: At Week 2; At Week 4; At Week 12
Forced Expiratory Volume in 1 second（FEV1）
Time frame: At Week 2; At Week 4; At Week 12; At Week 24
Total Serum Immunoglobulin E (IgE)
Time frame: At Week 12; At Week 24
Nasal endoscopy
Time frame: After 12 weeks of treatment；After 24 weeks of treatment
Nasal Exhaled Nitric Oxide
Time frame: At Week 12; At Week 24
Heart Rate
Time frame: At Week 12; At Week 24
Body Temperature
Time frame: At Week 12; At Week 24
C-reactive protein (CRP)
Time frame: At Week 12; At Week 24
Alanine aminotransferase (ALT)
Time frame: At Week 12; At Week 24
Creatinine
Time frame: At Week 12; At Week 24
IgG, IgA, IgM, C3,C4
Time frame: At Week 12; At Week 24
Peak Expiratory Flow (PEF)
Time frame: At Week 2; At Week 4;At Week 12; At Week 24
Total Nasal Symptom Score (TNSS)
Time frame: At Week 2; At Week 4; At Week 12
Visual Analog Scale (VAS)
Time frame: At Week 2; At Week 4; At Week 12
Asthma Control Test (ACT)
Time frame: At Week 2; At Week 4; At Week 12
Specific Immunoglobulin E (sIgE)
Time frame: At Week 12; At Week 24
Immunoglobulin G4 (IgG4)
Time frame: At Week 12; At Week 24
Aspartate aminotransferase (AST)
Time frame: At Week 12; At Week 24
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Mar 2026.
- Individual participant dataSharing planned: No. The informed consent form of this study does not include clauses authorizing IPD sharing. As a Phase I/II exploratory study, the data involves sensitive medical information and preliminary research results. To protect participants' privacy and comply with ethical and regulatory requirements, the data will not be shared.
Related trials for Allergic Rhinitis
Not yet recruitingPhase 1
Safety and Tolerability of Fluticasone Propionate 10% Nasal Insert in Participants With Chronic Allergic Rhinitis
Chronic Allergic Rhinitis
RecruitingPhase 3
Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-063.
Allergic Rhinitis, Allergic Rhinoconjunctivitis
RecruitingPhase 3
Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063.
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Enrolling by invitationObservational study
Allergy, Asthma, and Atopic Eczema in Finland
Asthma, Asthma in Children
Not yet recruitingObservational study
Prevelance of Bronchial Asthma and Allergic Rhinitis Among Children With Nephrotic Syndrom at Sohag University Hospital
Allergic Diseases in Nephrotic Children, Nephrotic Syndrom
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yan Jiang, MD principal investigator
The Affiliated Hospital of Qingdao University
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing hUC-MSC-sEV-002 Nebulizer and hUC-MSC-sEV-002 Mimetic (Normal Saline) in people with Allergic Rhinitis and Asthma, run by The Affiliated Hospital of Qingdao University at 5 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yan Jiang, MD (+86-532-82915920, jiangyanoto@qdu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) (time frame: At Week 24). The study lists 18 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Mar 2026.